Ann: Mayne Pharma Signs European SUBACAP Distribu, page-2

re: Ann: Mayne Pharma Signs European SUBACAP ... Another step in the right direction with 2 marketing and distributions agreements for SUBACAP.

Isdin will market the product in Spain, Italy and Portugal whilst Glenmark will market it in the UK.

Under the distribution agreement Mayne Pharma will receive upfront and milestone payments upon certain launch hurdles and a percentage of net sales in each country. They are also in late stage discussions with Korea and are looking to commercialize SUBACAP in other key markets such as Japan and in the USA.

MYX didn’t say how much the deal was to net the company hence why IMO there was little reaction to the SP today and the product launch isn’t going to happen in the UK until the end of 2013 or in Spain, Italy and Portugal until 2014.


There has been good accumulation of MYX over the last month and I’m looking forward to the FY13 Financial Results which should be out around the 3rd week in August considering it was released last year on the 21st. MYX will also have a presentation with the report which should give shareholders more of an insight into their forward projections. With a lower AU dollar, additional acquisitions and hopefully FDA approvals in the later part of this calendar year MYX has plenty of potential.

Cheers Matsim